M
Michael Machuzak
Researcher at Cleveland Clinic
Publications - 90
Citations - 2400
Michael Machuzak is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Bronchoscopy & Lung transplantation. The author has an hindex of 19, co-authored 87 publications receiving 1840 citations. Previous affiliations of Michael Machuzak include University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM)
Gerard J. Criner,Richard Sue,Shawn Wright,Mark T. Dransfield,Hiram Rivas-Perez,Tanya Wiese,Frank C. Sciurba,Pallav L. Shah,Momen M. Wahidi,Hugo Goulart de Oliveira,Brian M. Morrissey,Paulo Francisco Guerreiro Cardoso,Steven R. Hays,Adnan Majid,Nicholas J. Pastis,Lisa Kopas,Mark Vollenweider,P. Michael McFadden,Michael Machuzak,David W. Hsia,Arthur Sung,Nabil Jarad,Malgorzata Kornaszewska,Stephen R. Hazelrigg,Ganesh Krishna,Brian Armstrong,Narinder S. Shargill,Dirk-Jan Slebos +27 more
TL;DR: EBV treatment in hyperinflated patients with heterogeneous emphysema without collateral ventilation resulted in clinically meaningful benefits in lung function, dyspnea, exercise tolerance, and quality of life, with an acceptable safety profile.
Journal ArticleDOI
A Multicenter RCT of Zephyr® Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE)
Gerard J. Criner,Richard Sue,Shawn Wright,Mark T. Dransfield,Hiram Rivas-Perez,Tanya Wiese,Frank C. Sciurba,Pallav L. Shah,Momen M. Wahidi,Hugo Goulart de Oliveira,Brian M. Morrissey,Paulo Francisco Guerreiro Cardoso,Steven R. Hays,Adnan Majid,Nicholas J. Pastis,Lisa Kopas,Mark Vollenweider,P. Michael McFadden,Michael Machuzak,David W. Hsia,Arthur Sung,Nabil Jarad,Malgorzata Kornaszewska,Stephen R. Hazelrigg,Ganesh Krishna,Brian Armstrong,Narinder S. Shargill,Dirk-Jan Slebos +27 more
TL;DR: Zephyr EBV provides clinically meaningful benefits in lung function, exercise tolerance, dyspnea, and quality of life out to at least 12 months, with an acceptable safety profile in patients with little or no collateral ventilation in the target lobe.
Journal ArticleDOI
A multicenter trial of an intrabronchial valve for treatment of severe emphysema.
Douglas E. Wood,Robert McKenna,Roger D. Yusen,Daniel H. Sterman,David Ost,Steven C. Springmeyer,H. Xavier Gonzalez,Michael S. Mulligan,Thomas R. Gildea,Ward Houck,Michael Machuzak,Atul C. Mehta +11 more
TL;DR: The Intrabronchial Valve as discussed by the authors is used to block bronchial airflow in the most emphysematous areas of lung, and it can provide palliation with less risk than lung volume reduction surgery.
Journal ArticleDOI
A Phase I Clinical Trial of Single-Dose Intrapleural IFN-β Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses
Daniel H. Sterman,Adri Recio,Richard G. Carroll,Colin T. Gillespie,Andrew R. Haas,Anil Vachani,Veena Kapoor,Jing Sun,Richard L. Hodinka,Jennifer L. Brown,Michael J. Corbley,Michael Parr,Mitchell Ho,Ira Pastan,Michael Machuzak,William F. Benedict,Xin Qiao Zhang,Elaina M. Lord,Leslie A. Litzky,Daniel F. Heitjan,Carl H. June,Larry R. Kaiser,Robert H. Vonderheide,Steven M. Albelda +23 more
TL;DR: Intrapleural instillation of Ad.IFN-β is a potentially useful approach for the generation of antitumor immune responses in MPM and MPE patients and should be investigated further for overall clinical efficacy.
Journal ArticleDOI
Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients.
Kevin L. Stephans,Toufik Djemil,Chandana A. Reddy,S. Gajdos,Mathew Kolar,Michael Machuzak,Peter J. Mazzone,Gregory M.M. Videtic +7 more
TL;DR: Although patients dying of cardiac disease died earlier than those dying of other causes, FEV1% below median was not associated with a lower risk of dying of heart disease or with lower Charlson comorbidity index.